Send to

Choose Destination
Transplant Proc. 1996 Apr;28(2):925-9.

Pharmacokinetics of mycophenolate mofetil (RS61443): a short review.

Author information

Roche Bioscience, Palo Alto, California 94303, USA.


Overall, the PK of MMF is reasonably straightforward and relatively unaffected by the complex pathophysiological changes involved in the management of renal transplant recipients. The ability to relate plasma MPA concentrations to efficacy through the PK/PD correlation implies that, unlike for many other drugs, plasma PK has direct relevance to the clinical outcome. These features should not only greatly help the exploration of immunosuppressive regiments using MMF but also the development of clinical use of MMF in situations other than renal transplantation.

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center